Endocannabinoids in striatal plasticity

Parkinsonism and Related Disorders

Volumn 18, Issue SUPPL. 1, 2012, Pages

  Lovinger, David M ^a   Mathur, Brian N ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

Dopamine; GABA; Glutamate; Parkinson's disease

Indexed keywords

4 AMINOBUTYRIC ACID; AMPA RECEPTOR; CANNABINOID 1 RECEPTOR; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; ENDOCANNABINOID; GLUTAMIC ACID; LEVODOPA; METABOTROPIC RECEPTOR 1;

ADVERSE OUTCOME; ARTICLE; CATECHOLAMINE DEPLETION; CORPUS STRIATUM; DISEASE ASSOCIATION; DYSKINESIA; HUMAN; INTRACELLULAR SIGNALING; LONG TERM DEPRESSION; NERVE CELL PLASTICITY; NEUROCHEMISTRY; NEUROMODULATION; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RECEPTOR BINDING; SYNAPSE; TISSUE DISTRIBUTION;

EID: 84858654825     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/s1353-8020(11)70041-4     Document Type: Article

References (20)

1. Gainetdinov RR, Wetsel WC, Jones SR, Levin ED, Jaber M, Caron MG. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science 1999;283:397-401.
2. Calabresi P, Maj R, Mercuri NB, Bernardi G. Coactivation of D1 and D2 dopamine receptors is required for long-term synaptic depression in the striatum. Neurosci Lett 1992;142(1):95-9.
3. Lovinger DM. Presynaptic modulation by endocannabinoids. Handb Exp Pharmacol 2008;(184):435-77.
4. Di Marzo V, De Petrocellis L. Endocannabinoids as regulators of transient receptor potential (TRP) channels: A further opportunity to develop new endocannabinoid-based therapeutic drugs. Curr Med Chem 2010;17(14): 1430-49.
5. Ferńandez-Ruiz J. The endocannabinoid system as a target for the treatment of motor dysfunction. Br J Pharmacol 2009;156(7):1029-40.
6. Lovinger DM. Neurotransmitter roles in synaptic modulation, plasticity and learning in the dorsal striatum. Neuropharmacology 2010;58(7):951-61.
7. Calabresi P, Picconi B, Tozzi A, Di Filippo M. Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends Neurosci 2007;30(5):211-9.
8. Wang Z, Kai L, Day M, Ronesi J, Yin HH, Ding J, et al. Dopaminergic control of corticostriatal long-term synaptic depression in medium spiny neurons is mediated by cholinergic interneurons. Neuron 2006;50:443-52.
9. Singla S, Kreitzer AC, Malenka RC. Mechanisms for synapse specificity during striatal long-term depression. J Neurosci 2007;27(19):5260-4.
10. Mathur BN, Lovinger DL. State-dependent selection of endocannabinoid type mediates microcircuit-specific forms of inhibitory LTD in the dorsal striatum. Society for Neuroscience Abstracts 2011; available online at http://www.abstractsonline.com/Plan/SSResults.aspx.
11. Kreitzer AC, Malenka RC. Dopamine modulation of state-dependent endocannabinoid release and long-term depression in the striatum. J Neurosci 2005;25(45):10537-45.
12. 2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990;250:1429-32.
13. Kreitzer AC, Malenka RC. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature 2007;445(7128):643-7.
14. Shen W, Flajolet M, Greengard P, Surmeier DJ. Dichotomous dopaminergic control of striatal synaptic plasticity. Science 2008;321(5890):848-51.
15. Bagetta V, Picconi B, Marinucci S, Sgobio C, Pendolino V, Ghiglieri V, et al. Dopamine-dependent long-term depression is expressed in striatal spiny neurons of both direct and indirect pathways: implications for Parkinson's disease. J Neurosci 2011;31(35):12513-22.
16. Picconi B, Bagetta V, Ghiglieri V, Paill 'e V, Di Filippo M, Pendolino V, et al. Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia. Brain 2011;134(Pt 2):375-87.
17. Gubellini P, Picconi B, Bari M, Battista N, Calabresi P, Centonze D, et al. Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J Neurosci 2002;22:6900-7.
18. Kurz A, Double KL, Lastres-Becker I, Tozzi A, Tantucci M, Bockhart V, et al. A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice. PLoS One 2010;5(7):e11464.
19. Pisani V, Moschella V, Bari M, Fezza F, Galati S, Bernardi G, et al. Dynamic changes of anandamide in the cerebrospinal fluid of Parkinson's disease patients. Mov Disord 2010;25(7):920-4.
20. Van Laere K, Casteels C, Lunskens S, Goffin K, Grachev ID, Bormans G, et al. Regional changes in type 1 cannabinoid receptor availability in Parkinson's disease in vivo. Neurobiol Aging 2011; e-pub available online.